Abstract
Resistance to antitumor agents has been known to occur within tumour tissue since its discovery by Burchenal and his colleagues in 1950. Its meaning in the experimental laboratory may differ from that in the clinic in several important ways, stemming from the difference in the parameters with which it is possible to identify and measure it in each situation. The clinical experience is that of the patient who, following an initial success after treatment with the same initially active drug. the clinician is then faced with the problem of trying to identify another anticancer drug to which he can turn, in order, hopefully, to effect a suitable regression which would benefit the patient at least as much as the first dose of the earlier drug.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Peterson RHF, Meyex MB, Spengler A, Biedler JL: Alteration of plasma membrane glycopeptides and gangliosides of Chinese hamster cells accompanying development of resistance to Daunorubicin and Vincristine, Cancer Res (43): 222–228, 1983.
Juliano RL, Ling VA: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta (455): 152 Mechanisms of Resistance to
Editor information
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Fox, B.W. (1984). Mechanisms of Resistance to Anticancer Agents. In: Harrap, K.R., Davis, W., Calvert, A.H. (eds) Cancer Chemotherapy and Selective Drug Development. Developments in Oncology, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3837-6_32
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3837-6_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3839-0
Online ISBN: 978-1-4613-3837-6
eBook Packages: Springer Book Archive